Goldman Sachs Group Inc Ultragenyx Pharmaceutical Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 553,670 shares of RARE stock, worth $23.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

553,670

Previous 506,510 9.31%

Holding current value

$23.6 Million

Previous $28.1 Million 17.22%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$42.07 - $57.72 $1.98 Million - $2.72 Million	47,160 Added 9.31%	553,670 $23.3 Million
Q3 2024 Nov 14, 2024	SELL	$40.21 - $59.36 $4.95 Million - $7.3 Million	-123,004 Reduced 19.54%	506,510 $28.1 Million
Q2 2024 Aug 13, 2024	BUY	$37.42 - $51.61 $9.93 Million - $13.7 Million	265,392 Added 72.89%	629,514 $25.9 Million
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $8.99 Million - $11.2 Million	209,070 Added 134.84%	364,122 $17 Million
Q4 2023 Feb 13, 2024	SELL	$31.73 - $49.19 $7.5 Million - $11.6 Million	-236,251 Reduced 60.38%	155,052 $7.41 Million
Q3 2023 May 14, 2024	BUY	$34.92 - $46.66 $8.25 Million - $11 Million	236,251 Added 152.37%	391,303 $13.9 Million
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $5.08 Million - $6.79 Million	-145,425 Reduced 27.09%	391,303 $13.9 Million
Q2 2023 May 14, 2024	BUY	$37.35 - $52.15 $3.43 Million - $4.78 Million	91,721 Added 20.61%	536,728 $24.8 Million
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $3.43 Million - $4.78 Million	91,721 Added 20.61%	536,728 $24.8 Million
Q1 2023 May 14, 2024	SELL	$36.99 - $48.71 $24.8 Million - $32.6 Million	-669,311 Reduced 60.06%	445,007 $17.8 Million
Q1 2023 May 11, 2023	SELL	$36.99 - $48.71 $24.8 Million - $32.6 Million	-669,311 Reduced 60.06%	445,007 $17.8 Million
Q4 2022 May 14, 2024	BUY	$33.72 - $46.33 $3.48 Million - $4.78 Million	103,130 Added 10.2%	1,114,318 $51.6 Million
Q4 2022 Feb 13, 2023	BUY	$33.72 - $46.33 $3.48 Million - $4.78 Million	103,130 Added 10.2%	1,114,318 $51.6 Million
Q3 2022 May 14, 2024	BUY	$39.96 - $66.14 $6.04 Million - $9.99 Million	151,113 Added 17.57%	1,011,188 $41.9 Million
Q3 2022 Nov 10, 2022	BUY	$39.96 - $66.14 $6.04 Million - $9.99 Million	151,113 Added 17.57%	1,011,188 $41.9 Million
Q2 2022 May 14, 2024	BUY	$45.8 - $85.4 $32.3 Million - $60.2 Million	705,023 Added 454.7%	860,075 $51.3 Million
Q2 2022 Aug 15, 2022	BUY	$45.8 - $85.4 $4.25 Million - $7.93 Million	92,834 Added 12.1%	860,075 $51.3 Million
Q1 2022 May 16, 2022	BUY	$62.2 - $84.4 $2.59 Million - $3.51 Million	41,563 Added 5.73%	767,241 $55.7 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $16.2 Million - $19.3 Million	219,470 Added 43.36%	725,678 $61 Million
Q3 2021 Nov 10, 2021	BUY	$77.92 - $102.4 $39.4 Million - $51.8 Million	506,208 New	506,208 $45.7 Million

Others Institutions Holding RARE

# of Institutions

344

Shares Held

86.6M

Call Options Held

675K

Put Options Held

846K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.98B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Ultragenyx Pharmaceutical Inc. Transaction History